Updated: Oct 15
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
Michael, a 59-year-old patient from New Zealand with advanced gastroduodenal adenocarcinoma, traveled roughly 9,000 kilometers to China to access satri-cel (CT041), the world's first approved CAR-T therapy for a solid tumor. For international patients whose cancers have progressed through standard treatment and who meet the biomarker and clinical criteria for this newly approved therapy, ChinaCureLink can help coordinate medical record review, specialist matching, treatment arrangements, and the practical logistics of receiving care in China.
Key Takeaways |
|
Patient Background
Michael was diagnosed with advanced gastroduodenal adenocarcinoma in late 2025. He underwent chemotherapy combined with immunotherapy in New Zealand, but his disease continued to progress.
As conventional treatment options became increasingly limited, Michael began searching online for emerging cancer treatments available internationally. His search took him beyond the treatment options available in his home country and ultimately to China.
The turning point was the approval of satri-cel, a Claudin 18.2-targeted CAR-T therapy developed specifically for advanced gastric and gastroesophageal junction adenocarcinoma. China became the first country to approve a CAR-T therapy for a solid-tumor indication, creating an access pathway that was not yet available to patients in most other countries.
The Care Team and Approach
Before traveling to China, Michael worked with the medical team to complete biomarker testing in New Zealand. His results showed Claudin 18.2 positivity and HER2 negativity, matching the approved patient profile for satri-cel.
He then traveled to Shanghai with his family and underwent a comprehensive evaluation at an international cancer center. This included PET-CT imaging, multidisciplinary assessment, treatment planning, and the collection of his own T cells.
Satri-cel is an autologous CAR-T therapy. T cells are collected from the patient and used to manufacture genetically engineered cells designed to recognize Claudin 18.2 on cancer cells. The personalized CAR-T cells are then returned to the patient after manufacturing and preparation.
Michael arrived in China with significant disease-related complications, including severe malignant ascites and difficulty eating. During the treatment period, his ascites required regular drainage, at times reaching approximately 2,000 milliliters per day. His care therefore involved not only the CAR-T treatment itself but also close management of the complications associated with his advanced disease.
Throughout the process, his medical team maintained close communication with him and his family, providing detailed explanations of his tests, treatment progress, and clinical results.
Treatment Timeline/ Process
In New Zealand
Late 2025: Diagnosed with advanced gastroduodenal adenocarcinoma
Received chemotherapy combined with immunotherapy
Disease continued to progress despite standard systemic treatment
Began researching international treatment options as locally available choices became increasingly limited
Completed preliminary Claudin 18.2 and HER2 biomarker testing before traveling to China
In China
June 2026: Traveled from New Zealand to Shanghai after China approved satri-cel for eligible advanced gastric and gastroesophageal junction adenocarcinoma
Biomarker results confirmed Claudin 18.2 positivity and HER2 negativity
Underwent PET-CT, multidisciplinary evaluation, and treatment planning
July 6, 2026: Completed T-cell collection for personalized CAR-T manufacturing
Received the manufactured CAR-T treatment following the required preparation and treatment process
During treatment, severe malignant ascites and difficulty eating were actively managed, with drainage requirements reaching approximately 2,000 milliliters per day at their peak
Over more than a month of care, his clinical condition improved sufficiently for discharge and return home
Returning to New Zealand
August 16, 2026: Completed his treatment in Shanghai and was discharged
Before departure, his Chinese medical team prepared a detailed follow-up plan
His treating physician in China communicated directly with his doctor in New Zealand to coordinate ongoing care and monitoring
Solid-Tumor CAR-T Treatment in China: Outcome
Michael completed more than a month of Solid-tumor CAR-T treatment in China and was discharged on August 16, 2026, returning to New Zealand for continued follow-up.
His severe malignant ascites had been a major complication during treatment, requiring frequent drainage before improving enough for him to leave hospital. By discharge, he was able to resume a more normal diet, including soups and ice cream, and travel home independently.
The Chinese and New Zealand medical teams also established a cross-border follow-up plan so that his ongoing examinations and cancer monitoring could continue after his return.
His case demonstrates the practical pathway now available to eligible international patients seeking satri-cel in China: biomarker confirmation before travel, specialist assessment in China, personalized T-cell collection and manufacturing, CAR-T treatment, management of treatment-related and disease-related complications, and coordinated follow-up after returning home.
How ChinaCureLink Can Help International Patients to Access This Treatment
Michael's journey shows how quickly access to a newly approved cancer therapy can become international when the treatment is not yet available in a patient's home country. ChinaCureLink can help patients with advanced gastric or gastroesophageal junction adenocarcinoma determine whether their medical history and biomarker profile may fit the requirements for satri-cel, arrange specialist review, and coordinate the practical steps required to travel to China.
This can include medical-record collection and translation, pathology and biomarker review, hospital and specialist matching, treatment scheduling, travel and accommodation coordination, interpretation, and communication between the Chinese and home-country medical teams.
For patients returning home after treatment, cross-border coordination is equally important. Ongoing imaging, laboratory testing, oncology review, and monitoring can be planned with the receiving medical team so that treatment does not end simply because the patient leaves China.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Who may be eligible for satri-cel CAR-T therapy in China?
Satri-cel is approved in China for patients with Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma whose disease has progressed after at least two prior lines of treatment. Individual eligibility requires a specialist assessment of the patient's complete medical history, pathology, biomarkers, and current condition.
How much does satri-cel CAR-T treatment cost in China?
The published price of the satri-cel treatment itself is RMB 990,000 per patient dose. The total cost of receiving treatment in China can be higher once specialist assessment, testing, hospitalization, supportive care, travel, accommodation, and follow-up are included. ChinaCureLink can arrange a case-specific cost assessment after medical records have been reviewed.
Can I return to my home country after CAR-T treatment in China?
Yes. International patients can return home after completing the appropriate treatment and immediate monitoring period, with continued follow-up coordinated between the Chinese treatment team and their doctors at home. The exact timing depends on the individual patient's condition and the treating team's assessment.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This account reflects one patient's individual experience, which will vary by case, diagnosis stage, and other clinical factors. ChinaCureLink facilitates access to hospitals and treatment coordination — we do not provide medical care ourselves, and this content is not medical advice. Patients and families should consult a qualified medical oncologist before making treatment decisions.
